FOENIX / TAS120
29 Nov 2021
FOENIX / TAS120
NCT04093362
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3
Taiho Oncology, Inc.
Cancer Type | Other |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | Advanced Cholangeiocarcinoma FGFR2 gene rearrangements |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2020-03-01 |
Anticipated End Date | 2025-04-01 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Hannah Adelson |
Hannah.adelson@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs